# A Study of Investigational Agents in Participants With Previously Treated Stage IV Nonsquamous Non-small Cell Lung Cancer (NSCLC) (MK-3475-01H/KEYMAKER-U01)

Source: https://onco.cc/trials/nct06780085/  
OnCo record `nct06780085` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of Raludotatug deruxtecan and Ifinatamab deruxtecan in non-small-cell lung cancer, run by Merck Sharp & Dohme LLC, now recruiting.

## Summary

A Study of Investigational Agents in Participants With Previously Treated Stage IV Nonsquamous Non-small Cell Lung Cancer (NSCLC) (MK-3475-01H/KEYMAKER-U01) is a phase 2 interventional study registered as NCT06780085 by Merck Sharp & Dohme LLC, with 96 participants planned, started 2025-05-13 and due to reach its primary completion in 2032-03-12. Interventions recorded: Raludotatug Deruxtecan, Ifinatamab Deruxtecan, Docetetaxel, 5-hydroxytryptamine subtype 3 receptor antagonist, Neurokinin-1 receptor antagonist and Corticosteroid.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT06780085
- Phase: 2
- Setting: KEYMAKER-U01 Substudy 01H: A Phase 2, Randomized, Umbrella Study With Rolling Arms of Investigational Agents in Participants With Previously Treated Stage IV Nonsquamous Non-small Cell Lung Cancer (NSCLC)
- Sponsor: Merck Sharp & Dohme LLC
- Enrolled: 96

## Sources

- ClinicalTrials.gov NCT06780085: https://clinicaltrials.gov/study/NCT06780085

## Connected records

- cancers: [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/)
- drugs: [Ifinatamab deruxtecan](https://onco.cc/drugs/ifinatamab-deruxtecan/), [Raludotatug deruxtecan](https://onco.cc/drugs/raludotatug-deruxtecan/)
- companies: [Daiichi Sankyo](https://onco.cc/companies/daiichi-sankyo/), [Merck & Co. (MSD)](https://onco.cc/companies/merck/)

---
JSON: https://onco.cc/api/v1/entities/nct06780085.json